What does current research indicate regarding the efficacy and safety of ivermectin for off‑label uses such as viral, bacterial, or inflammatory diseases?

Ivermectin Should NOT Be Used for Off-Label Indications Like COVID-19 or Other Viral/Inflammatory Diseases

Ivermectin is FDA-approved exclusively for parasitic infections (strongyloidiasis and onchocerciasis), and current evidence does not support its use for COVID-19, viral infections, bacterial infections, or inflammatory diseases outside of clinical trials. 1

FDA-Approved Indications Only

The FDA label is clear: ivermectin is indicated solely for:

• Intestinal strongyloidiasis (nematode parasite Strongyloides stercoralis)
• Onchocerciasis (nematode parasite Onchocerca volvulus)

The drug works by binding to glutamate-gated chloride channels in invertebrate nerve and muscle cells, causing paralysis and death of parasites. Importantly, ivermectin does not readily cross the blood-brain barrier in humans and has low affinity for mammalian chloride channels, which explains its selective antiparasitic activity. 1

COVID-19: Strong Evidence Against Use

Major Guideline Recommendations

Both the Infectious Diseases Society of America (IDSA) and World Health Organization (WHO) recommend against ivermectin for COVID-19:

For hospitalized patients with COVID-19:

• No meaningful effect on mortality (RR: 0.54; 95% CI: 0.28-1.03; moderate certainty)
• No benefit for mechanical ventilation need (RR: 0.40; 95% CI: 0.13-1.27; low certainty)
• No effect on symptom resolution or viral clearance at day 7
• The IDSA conditionally recommends against ivermectin outside clinical trials 2

For outpatient/ambulatory COVID-19:

• No reduction in mortality (RR: 0.83; 95% CI: 0.50-1.37; high certainty)
• No benefit for hospitalization (RR: 0.85; 95% CI: 0.65-1.11; moderate certainty)
• No effect on viral clearance
• The IDSA recommends against ivermectin for outpatients 2

The WHO updated its guidance in 2024, reinforcing that ivermectin should not be used for COVID-19 treatment in patients with non-severe illness based on additional trial evidence. 3

Recent High-Quality Research Confirms No Benefit

A 2024 systematic review and meta-analysis of 12 RCTs with 7,035 participants found:

• No reduction in hospitalization (RR 0.81,95% CI 0.64-1.03)
• No reduction in mortality (RR 0.98,95% CI 0.73-1.33)
• No reduction in adverse events (RR 0.89,95% CI 0.75-1.07)
• No effect on mechanical ventilation, clinical worsening, or viral clearance

The authors concluded: "Ivermectin should not be recommended as treatment in non-hospitalized COVID-19 patients." 4

Safety Concerns

A 2022 double-blind RCT from Thailand (983 participants) found:

• No efficacy for prevention (COVID-19 incidence: 4.7% vs 5.2% placebo; p=0.844)
• No efficacy for treatment (no difference in oxygen desaturation, WHO score, or symptom resolution)
• Significantly higher rate of transient blurred vision (5.6% vs 0.6%; p<0.001) 5

The IDSA notes that serious adverse events cannot be excluded (RR: 3.10; 95% CI: 0.54-17.89 for hospitalized patients). 2

Critical Methodological Issues in Existing Studies

The IDSA guideline panel identified major quality concerns:

• High risk of bias in multiple trials due to inadequate randomization (e.g., allocation by odd/even days, all critically ill patients assigned to ivermectin arm)
• Lack of blinding in many studies
• Substantial heterogeneity between studies
• Very low to low certainty of evidence for most outcomes 2

Other Off-Label Uses: Insufficient Evidence

While laboratory studies suggest potential anti-inflammatory, antiviral, and anticancer properties through mechanisms like NF-κB pathway inhibition and importin α/β1 interference, these are in vitro findings that have not translated to clinical efficacy. 6

The 2021 Cochrane review concluded: "The reliable evidence available does not support the use of ivermectin for treatment or prevention of COVID-19 outside of well-designed randomized trials." 7

What to Tell Patients

When patients ask about ivermectin:

1. Acknowledge their concern but explain that ivermectin is only proven effective for specific parasitic infections
2. Present the evidence: Multiple large, high-quality studies and major medical organizations (IDSA, WHO) have found no benefit for COVID-19
3. Discuss risks: Even "safe" drugs can cause harm when used inappropriately (e.g., blurred vision, potential drug interactions via CYP3A4)
4. Redirect to proven therapies: For COVID-19, discuss evidence-based treatments like nirmatrelvir/ritonavir for high-risk patients
5. Avoid dismissiveness: Patients seeking ivermectin often feel unheard; validate their desire for effective treatment while steering toward evidence-based options

Common Pitfalls to Avoid

• Don't prescribe based on anecdotal reports or low-quality studies: The highest quality evidence consistently shows no benefit
• Don't assume "it can't hurt": Ivermectin has drug interactions (CYP3A4 metabolism) and can cause adverse effects, especially at higher doses 1
• Don't confuse antiparasitic efficacy with antiviral efficacy: The mechanism that works against parasites does not translate to viral infections in humans at achievable drug concentrations

The bottom line: Ivermectin should be reserved for its FDA-approved parasitic indications only. 1